OpGen Releases Preliminary Data Demonstrating its Unyvero HPN Panel for Pneumonia Identifies Life-Threatening Bacterial Co-Infections in COVID-19 Patients in Just Five Hours
09. Juni 2020 07:30 ET
|
OpGen, Inc.
Performance of the Unyvero HPN Panel for pneumonia proves to be strongly concordant (98.2%) compared to bacterial lower respiratory tract culture Collaboration with Karolinska Institutet highlights...
OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections
03. Juni 2020 06:00 ET
|
OpGen, Inc.
Collaboration with NYS Department of Health’s Wadsworth Center continues for second year term Project to utilize OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health...
U.S. Patent Allowed Covering Acuitas Lighthouse® Software
23. Oktober 2019 07:30 ET
|
OpGen, Inc.
GAITHERSBURG, Md., Oct. 23, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that the United States Patent and Trademark Office (the “USPTO”) has allowed a key OpGen patent...
OpGen Presents Preliminary Acuitas® AMR Gene Panel Data for Detecting Urinary Tract Infections
07. Oktober 2019 07:30 ET
|
OpGen, Inc.
GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) today announced the presentation of preliminary data at IDWeek 2019 for the Company’s Acuitas® AMR Gene Panel and...
OpGen Provides update on Curetis Group’s R&D Collaboration
18. September 2019 07:30 ET
|
OpGen, Inc.
Curetis R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdbCollaborator to fund R&D and obtains option to license ARESdb and ARES Technology...
Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
04. September 2019 06:55 ET
|
OpGen, Inc.
Combined company creates a commercial-stage, transatlantic diagnostics company focusing on data-driven solutions for molecular microbiologyCombined company to be headquartered in Gaithersburg, MD,...
OpGen’s Acuitas® AMR Gene Panel Shows Potential for Reducing Total Time to Targeted Therapy
27. Juni 2019 07:30 ET
|
OpGen, Inc.
Collaborator data demonstrating OpGen’s rapid prediction of antibiotic resistance and detection of uropathogens presented at ASM Microbe 2019 GAITHERSBURG, Md., June 27, 2019 (GLOBE NEWSWIRE) --...